
This photo provided by Samsung E&A Co. shows a rendered image of an upcoming biopharmaceutical raw material production and research facility in Songdo, west of Seoul, for Sartorius AG of Germany. (Image courtesy of Yonhap)
SEOUL, March 24 (Korea Bizwire) — Samsung E&A Co. said Monday it has secured a 518.6 billion-won (US$354.2 million) contract to build a biopharmaceutical raw material production and research facility in Songdo, west of Seoul, for Sartorius AG of Germany.
The plant will be constructed for Sartorius Korea, the South Korean unit of the German life sciences giant, within the Songdo Free Economic Zone in Incheon.
Once completed, the facility will manufacture single-use bio processing bags and pharmaceutical membrane filters, while also providing clinical contract research organization (CRO) services.
Samsung E&A will handle the engineering, procurement and construction independently, with the project completion scheduled for 2027.
(Yonhap)